Standard BioTools (LAB) Q3 2026 earnings summary

Executive summary

• Q3 revenue was $19.4M, down 1% YoY; gross margin improved to 55.9% from 48.5%, while continuing operations recorded a $15.0M net loss. A $30.0M Illumina-related gain drove total net income to $13.5M.

• Strategic transition advanced through the planned Treeline merger and sales of the mass cytometry and microfluidics businesses.

Financial highlights

• Q3 product revenue rose 4% YoY to $14.3M: instruments increased 18% to $6.0M, while consumables declined 4% to $8.3M; services and other revenue fell 12% to $5.1M.

• Nine-month revenue was $60.6M, down 1% YoY; gross profit rose 5% to $32.7M, with gross margin at 53.9% versus 50.6%.

• Q3 operating expenses fell 28% to $30.6M; continuing-operations net loss narrowed to $15.0M from $31.7M.

• Nine-month total net income was $113.8M versus a $94.2M loss, including $164.9M income from discontinued operations.

Outlook and guidance

• Merger with Treeline was expected to close in Q4 2026, subject to customary conditions and stockholder approval; the stockholder meeting was scheduled for November 19, 2026.

• Existing liquidity and capital sources were expected to support operations for at least 12 months from the filing date.

• Consumables are expected to remain a substantial portion of revenue and grow over time through higher utilization, a larger installed base, and new offerings.